TransCode Therapeutics announced updated Phase 1a trial results for TTX-MC138, an RNA-based cancer therapy targeting advanced solid tumors. Among 14 evaluable patients, 71.4% achieved stable disease, with over half maintaining control through three months and about 37% through six months. Three patients remained progression-free at one year, and no dose-limiting toxicities were reported. The study met its primary endpoint, highlighting potential for TTX-MC138 in treating difficult cancers and supporting further development.
TransCode Therapeutics' clinical trial update is presented here with relevant market data. For readers following the health sector, 22 of 100 priced US health stocks on Pluang rose while 59 fell. ALNY was up 1.49% at USD 259.77 with a typical hold time of 40 days, ILMN was down 1.47% at USD 266.04 with a hold time of 86 days, and ACB fell 1.46% to USD 4.04 with a 26-day hold time, as of Sep 28, 2026 18:42 WIB.
Silver Elephant Mining Corp. announced that all resolutions at its September 25, 2026 Annual General Meeting were approved by shareholders. This included setting the number of directors at four and electing all nominated directors with over 96% appro...
Tom Lee, co-founder of Fundstrat Global Advisors, highlighted Ethereum's recent outperformance against traditional macro assets, suggesting that institutional investors might increase their Ethereum holdings later in 2026. This view frames Ethereum's...
RideNow Group has secured a $220 million senior secured term loan with Centerbridge Partners, extending its debt maturity to September 2031. This refinancing replaces its previous loan with Oaktree Fund Administration, reducing near-term debt risks a...
Levi Strauss shares have fallen about 7% in the last month ahead of its Q3 earnings report scheduled for October 7. This pullback follows a strong second quarter where the company raised its guidance, suggesting solid performance. Currently, the stoc...
SpaceX successfully launched its Starship rocket into Earth orbit for the first time, overcoming the loss of one of its six Raptor engines shortly after upper stage separation. Initially, the company paused the orbit attempt but then resumed, marking...
